Advertisement

Tumor Biology

, Volume 35, Issue 2, pp 955–959 | Cite as

Association between SOD2 C47T polymorphism and lung cancer susceptibility: a meta-analysis

Research Article

Abstract

Lung cancer is one of the most common cancers worldwide, but its etiology is still unclear. Superoxide dismutase 2 (SOD2) plays an essential role in oxidative stress and may be involved in the development of lung cancer. The association between SOD2 C47T polymorphism and lung cancer risk has been widely investigated, but the results of previous studies are contradictory. We conducted a meta-analysis to comprehensively assess the association between SOD2 C47T polymorphism and lung cancer. The association was estimated by odds ratio (OR) with 95 % confidence interval (95 % CI). A total of 10 studies with 5,146 cases and 6,173 controls were identified. The results showed that SOD2 C47T polymorphism was significantly associated with lung cancer (T versus C: OR = 0.88, 95 % CI = 0.83–0.93, P < 0.001; TT versus CC: OR = 0.74, 95 % CI = 0.66–0.83, P < 0.001; TT versus CC/CT: OR = 0.81, 95 % CI = 0.73–0.89, P < 0.001). Subgroup analysis by ethnicity suggested that SOD2 C47T polymorphism was significantly associated with lung cancer in both East Asians and Caucasians. Conclusively, this meta-analysis strongly suggests that SOD2 C47T polymorphism is significantly associated with lung cancer.

Keywords

Lung cancer SOD2 Polymorphism 

Notes

Acknowledgments

This work was supported in part by the grants from National Natural Science Foundation of China (No. 81300015, GS Zhang) and Qianjiang Talent Program (No. 2013R10050, GS Zhang) of Zhejiang Province, China.

Conflicts of interest

None

References

  1. 1.
    Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359:1367–80.PubMedCrossRefGoogle Scholar
  2. 2.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRefGoogle Scholar
  3. 3.
    Powell JW, Dexter E, Scalzetti EM, Bogart JA. Treatment advances for medically inoperable non-small-cell lung cancer: emphasis on prospective trials. Lancet Oncol. 2009;10:885–94.PubMedCrossRefGoogle Scholar
  4. 4.
    Goldstraw P, Ball D, Jett JR, et al. Non-small-cell lung cancer. Lancet. 2011;378:1727–40.PubMedCrossRefGoogle Scholar
  5. 5.
    Coate LE, John T, Tsao MS, Shepherd FA. Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet Oncol. 2009;10:1001–10.PubMedCrossRefGoogle Scholar
  6. 6.
    Brennan P, Hainaut P, Boffetta P. Genetics of lung-cancer susceptibility. Lancet Oncol. 2011;12:399–408.PubMedCrossRefGoogle Scholar
  7. 7.
    West XZ, Malinin NL, Merkulova AA, et al. Oxidative stress induces angiogenesis by activating tlr2 with novel endogenous ligands. Nature. 2010;467:972–6.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Perl A, Hanczko R, Telarico T, Oaks Z, Landas S. Oxidative stress, inflammation and carcinogenesis are controlled through the pentose phosphate pathway by transaldolase. Trends Mol Med. 2011;17:395–403.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Dhar SK, St Clair DK. Manganese superoxide dismutase regulation and cancer. Free Radic Biol Med. 2012;52:2209–22.PubMedCrossRefGoogle Scholar
  10. 10.
    Massaad CA, Klann E. Reactive oxygen species in the regulation of synaptic plasticity and memory. Antioxid Redox Signal. 2011;14:2013–54.PubMedCrossRefGoogle Scholar
  11. 11.
    Mates JM, Segura JA, Alonso FJ, Marquez J. Oxidative stress in apoptosis and cancer: an update. Arch Toxicol. 2012;86:1649–65.PubMedCrossRefGoogle Scholar
  12. 12.
    Broering EP, Truong PT, Gale EM, Harrop TC. Synthetic analogues of nickel superoxide dismutase: a new role for nickel in biology. Biochemistry. 2013;52:4–18.PubMedCrossRefGoogle Scholar
  13. 13.
    Wang LI, Miller DP, Sai Y, et al. Manganese superoxide dismutase alanine-to-valine polymorphism at codon 16 and lung cancer risk. J Natl Cancer Inst. 2001;93:1818–21.PubMedCrossRefGoogle Scholar
  14. 14.
    Lin P, Hsueh YM, Ko JL, Liang YF, Tsai KJ, Chen CY. Analysis of NQO1, GSTP1, and MNSOD genetic polymorphisms on lung cancer risk in Taiwan. Lung Cancer. 2003;40:123–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Liu G, Zhou W, Wang LI, et al. MPO and SOD2 polymorphisms, gender, and the risk of non-small cell lung carcinoma. Cancer Lett. 2004;214:69–79.PubMedCrossRefGoogle Scholar
  16. 16.
    Wang LI, Neuberg D, Christiani DC. Asbestos exposure, manganese superoxide dismutase (MNSOD) genotype, and lung cancer risk. J Occup Environ Med. 2004;46:556–64.PubMedCrossRefGoogle Scholar
  17. 17.
    Ho JC, Mak JC, Ho SP, et al. Manganese superoxide dismutase and catalase genetic polymorphisms, activity levels, and lung cancer risk in Chinese in Hong Kong. J Thorac Oncol. 2006;1:648–53.PubMedCrossRefGoogle Scholar
  18. 18.
    Liu Y, Xu ML, Zhong HH, Heng WJ, Wu BQ. EGFR mutations are more frequent in well-differentiated than in poor-differentiated lung adenocarcinomas. Pathol Oncol Res. 2008;14:373–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Zienolddiny S, Campa D, Lind H, et al. A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of non-small cell lung cancer in smokers. Carcinogenesis. 2008;29:1164–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCrossRefGoogle Scholar
  21. 21.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRefGoogle Scholar
  22. 22.
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMedGoogle Scholar
  23. 23.
    Lan Q, Mumford JL, Shen M, et al. Oxidative damage-related genes AKR1C3 and OGG1 modulate risks for lung cancer due to exposure to PAH-rich coal combustion emissions. Carcinogenesis. 2004;25:2177–81.PubMedCrossRefGoogle Scholar
  24. 24.
    Liu G, Zhou W, Park S, et al. The SOD2 val/val genotype enhances the risk of nonsmall cell lung carcinoma by p53 and XRCC1 polymorphisms. Cancer. 2004;101:2802–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Zejnilovic J, Akev N, Yilmaz H, Isbir T. Association between manganese superoxide dismutase polymorphism and risk of lung cancer. Cancer Genet Cytogenet. 2009;189:1–4.PubMedCrossRefGoogle Scholar
  26. 26.
    Huang SX, Wu FX, Luo M, et al. The glutathione S-transferase P1 341C>T polymorphism and cancer risk: a meta-analysis of 28 case–control studies. PLoS One. 2013;8:e56722.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Wang L, Cheng J, Gao J, Wang J, Liu X, Xiong L. Association between the NBS1 Glu185Gln polymorphism and lung cancer risk: a systemic review and meta-analysis. Mol Biol Rep. 2013;40:2711–5.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  1. 1.Department of Intensive Care UnitThe Second Affiliated Hospital of Zhejiang University School of MedicineHangzhouChina
  2. 2.Department of Respiratory MedicineThe Second Affiliated Hospital of Zhejiang University School of MedicineHangzhouChina

Personalised recommendations